Welcome to our dedicated page for Surrozen news (Ticker: SRZN), a resource for investors and traders seeking the latest updates and insights on Surrozen stock.
Surrozen, Inc. (Nasdaq: SRZN) is a biotechnology company developing Wnt pathway–modulating therapeutics with a focus on severe eye diseases, and its news flow reflects this ophthalmology and research orientation. Company press releases frequently highlight progress in its retinal disease pipeline, including updates on preclinical data for candidates such as SZN-8141, SZN-8143, and SZN-413, as well as plans related to regulatory milestones like an intended Investigational New Drug (IND) application for SZN-8141.
Investors following SRZN news can expect regular business updates tied to quarterly financial results, where Surrozen discusses research service revenue, operating expenses, and non-cash items alongside narrative commentary on pipeline momentum. These reports often describe how the company is leveraging its Wnt biology expertise and antibody technologies to advance programs in retinal vascular diseases.
Surrozen’s news stream also covers scientific and medical conference activity. The company reports presentations at ophthalmology-focused meetings such as the Association for Research in Vision and Ophthalmology (ARVO), Clinical Trials at the Summit, and various healthcare investor conferences. These announcements may include summaries of preclinical findings on Wnt-mediated retinal vascular repair and regeneration, as well as overviews of next-generation Wnt therapeutics in retinal diseases.
Corporate and governance developments are another recurring theme in SRZN news. Surrozen discloses leadership changes, including appointments to key roles like Chief Financial Officer and Vice President of Clinical Development, and reports inducement equity grants under Nasdaq Listing Rule 5635(c)(4). Updates on intellectual property, such as the issuance of U.S. patents related to its SWAP™ technology for multi-specific Wnt surrogates, and collaboration developments, including changes to related-party research agreements and details of its partnership with Boehringer Ingelheim, also appear in its announcements. For readers tracking SRZN, this news page aggregates these financial, scientific, and corporate updates in one place.
Surrozen, Inc. has completed its business combination with Consonance-HFW Acquisition Corp., set to commence trading on Nasdaq under the ticker symbols SRZN for common stock and SRZNW for warrants starting August 12, 2021. This merger was approved by the shareholders of both companies, and Surrozen aims to exploit the Wnt pathway for tissue repair. Management, led by CEO Craig Parker, believes this capital infusion will bolster their innovative therapeutic programs.
Surrozen, Inc. has completed its business combination with Consonance-HFW Acquisition Corp., a special purpose acquisition company. The merger was approved by shareholders on August 10, 2021, and will enable Surrozen to trade its shares on Nasdaq under the ticker symbol SRZN and its warrants as SRZNW beginning August 12, 2021. Surrozen aims to unlock therapeutic applications of the Wnt pathway for tissue repair and regeneration, with a management team led by CEO Craig Parker, focusing on developing innovative therapies for serious diseases.
Surrozen Inc. (Nasdaq: SRZN) has announced that CEO Craig Parker will present a company overview and business update at Canaccord Genuity’s 41st Annual Growth Conference on August 12, 2021, at 9:30 a.m. ET. Interested parties can access the live webcast on Surrozen's website, with a replay available afterward.
Surrozen focuses on developing drug candidates that selectively modulate the Wnt pathway, with applications in inflammatory bowel disease, hepatitis, eye diseases, and more. For further details, visit surrozen.com.